Alnylam Pharmaceuticals gets $750 million term loan with GSO Capital

By Devika Patel

Knoxville, Tenn., April 13 – Alnylam Pharmaceuticals, Inc. secured a $750 million first-lien senior secured term loan with lead lender GSO Capital Partners, according to a press release.

The loan was negotiated as part of a transaction under which Blackstone will provide up to $2 billion to support Alnylam’s advancement of innovative RNA interference medicines.

The transaction also includes the following:

• $1 billion in committed payments, led by Blackstone Life Sciences, to acquire 50% of Alnylam’s royalties and commercial milestones for inclisiran;

• Up to $150 million from Blackstone Life Sciences for development of Alnylam’s cardiometabolic programs vutrisiran and ALN-AGT; and

• A $100 million purchase of Alnylam common stock.

Based in Cambridge, Mass., Alnylam is a biopharmaceutical company focused on RNA interference technology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.